• 1. Evidence of rutile-to-anatase photo-induced electron transfer in mixed-phase TiO2 by solid-state NMR spectroscopy?
  Weili Dai,Guangjun Wu,Michael Hunger Chem. Commun., 2015,51, 13779-13782
• 2. Evolution of shape, size, and areal density of a single plane of Si nanocrystals embedded in SiO2 matrix studied by atom probe tomography
  Bin Han,Yasuo Shimizu,Gabriele Seguini,Celia Castro,Gérard Ben Assayag,Koji Inoue,Yasuyoshi Nagai,Sylvie Schamm-Chardon,Michele Perego RSC Adv., 2016,6, 3617-3622
• 3. Fc microparticles can modulate the physical extent and magnitude of complement activity?
  David White,Sean R. Stowell Biomater. Sci., 2017,5, 463-474
• 4. Enabling shape memory and healable effects in a conjugated polymer by incorporating siloxane via dynamic imine bond?
  Yaling Zhang,Chunhui Dai,Shiwei Zhou,Bin Liu Chem. Commun., 2018,54, 10092-10095
• 5. Embedding heteroatoms: an effective approach to create porphyrin-based functional materials
  Norihito Fukui,Keisuke Fujimoto,Hideki Yorimitsu,Atsuhiro Osuka Dalton Trans., 2017,46, 13322-13341

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyrrolidines N-alkylpyrrolidines

Recent Advances in Pyrrolidinium, 1-butyl-1-methyl-, iodide (CAS 56511-17-2) Research: Applications and Mechanistic Insights

The ionic liquid Pyrrolidinium, 1-butyl-1-methyl-, iodide (CAS 56511-17-2), commonly referred to as [BMP][I], has garnered significant attention in chemical biology and pharmaceutical research due to its unique physicochemical properties. Recent studies have explored its applications as a solvent, catalyst, and active pharmaceutical ingredient (API) intermediate. A 2023 study published in Journal of Molecular Liquids demonstrated its exceptional solvation capabilities for poorly water-soluble drugs, achieving 89% solubility enhancement for Class II BCS compounds when used as a co-solvent system.

Structural analyses using X-ray crystallography (XRD) and nuclear magnetic resonance (NMR) spectroscopy have revealed key interactions between the pyrrolidinium cation and biological targets. Research in ACS Medicinal Chemistry Letters (2024) identified specific hydrogen bonding patterns that contribute to its membrane permeability enhancement properties, with logP values optimized at 2.3-2.7 for blood-brain barrier penetration. These findings support its growing use in CNS drug formulations.

Significant progress has been made in understanding the compound's safety profile. Toxicological assessments conducted under OECD guidelines showed an LD50 of 1250 mg/kg in rodent models, with no observed genotoxicity at therapeutic concentrations. However, recent in vitro hepatocyte studies (2024) suggest dose-dependent cytochrome P450 inhibition, warranting careful pharmacokinetic evaluation in drug development pipelines.

The compound's role in green chemistry applications has expanded considerably. A breakthrough in Green Chemistry (2023) demonstrated its effectiveness as a recyclable catalyst in Pictet-Spengler reactions, achieving 92% yield with 99% enantiomeric excess. This positions [BMP][I] as a sustainable alternative to traditional organic solvents in asymmetric synthesis.

Emerging biomedical applications include its use as an antimicrobial agent. 2024 studies published in Biomaterials Science reported 4-log reduction in MRSA biofilm formation when incorporated into polymer matrices at 0.5% w/v concentration. The mechanism appears related to membrane disruption confirmed through atomic force microscopy (AFM) imaging.

Ongoing clinical research is investigating its potential in topical formulations. Phase I trials completed in Q1 2024 showed favorable dermal absorption profiles with less than 2% systemic bioavailability when applied as a 5% hydrogel. These results support its development for transdermal drug delivery systems currently in preclinical testing.

• 120186-29-0(Pyrrolidinium,1-ethyl-1-[5-(triethylammonio)pentyl]-, iodide (1:2))
• 63886-24-8(Pyrrolidinium,1,1'-(1,3-propanediyl)bis[1-methyl-, diiodide (9CI))
• 311-28-4(Tetrabutylammonium iodide)
• 63886-44-2(Pyrrolidinium,1,1'-(1,10-decanediyl)bis[1-methyl-, diiodide (9CI))
• 120-94-5(1-Methylpyrrolidine)
• 767-10-2(1-Butylpyrrolidine)
• 24715-90-0(4-(Pyrrolidin-1-yl)butan-1-amine)
• 13118-08-6(Pyrrolidinium,1,1'-hexamethylenebis[1-methyl-, diiodide (8CI))
• 56511-19-4(Pyrrolidinium, 1-methyl-1-propyl-, iodide)
• 63886-48-6(Pyrrolidinium,1,1'-(1,12-dodecanediyl)bis[1-methyl-, diiodide (9CI))